Veru Inc. (VERU)

Market Cap	37.24M
Revenue (ttm)	n/a
Net Income (ttm)	-22.73M
Shares Out	16.05M
EPS (ttm)	-1.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	266,896
Open	2.300
Previous Close	2.260
Day's Range	2.220 - 2.350
52-Week Range	2.110 - 14.200
Beta	-1.00
Analysts	Strong Buy
Price Target	25.00 (+977.59%)
Earnings Date	Dec 17, 2025

About VERU

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly pat...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 19, 1990
• Employees: 210
• Stock Exchange: NASDAQ
• Ticker Symbol: VERU
• Website: https://verupharma.com

Analyst Summary

According to 3 analysts, the average rating for VERU stock is "Strong Buy." The 12-month stock price target is $25.0, which is an increase of 977.59% from the latest price.

Price Target

$25.0

(977.59% upside)

Analyst Consensus: Strong Buy